China's crusade against pharma giants
China has taken Western pharmaceutical companies to task over alleged corruption in the country.
China's investigation into alleged corruption at pharmaceutical multi-nationals has widened in recent days. GlaxoSmithKline (GSK), accused last week of paying over $400m in bribes to doctors and lawyers to boost sales, admitted this week that senior executives "appear to have acted outside our processes and controls, which breaches Chinese law". Meanwhile, three AstraZeneca sales executives have been arrested, although the group was claiming early this week that they had no reason to believe the swoop was related to the bribery allegations.
What the commentators said
What's more, added The Wall Street Journal, the Chinese government's investigation didn't start as a criminal matter, but as a probe into the costs of drugs made by both domestic and foreign pharma groups. A foreign firm was targeted first because "that helps distract attention from a health system that relies on corruption to stay afloat".
Article continues belowTry 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Hospitals are forced to keep prices for most services below cost, so drug sales is one of the few areas in which they can make money. They encourage poorly paid doctors to prescribe more drugs by linking bonuses to revenue, while doctors also get kickbacks from drug firms. But instead of changing this "dysfunctional" cause of high drug prices, concluded The Wall Street Journal, China is "taking aim" at the likes of GSK.
